Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3
The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.